Original Article

You have free access to this content

Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery

  1. Hale B. Caglar MD1,
  2. Elizabeth H. Baldini MD, MPH1,
  3. Megan Othus MS2,
  4. Michael S. Rabin MD3,
  5. Raphael Bueno MD4,
  6. David J. Sugarbaker MD4,
  7. Steven J. Mentzer MD4,
  8. Pasi A. Jänne MD, PhD3,
  9. Bruce E. Johnson MD3,
  10. Aaron M. Allen MD1,†,*

Article first published online: 23 JUN 2009

DOI: 10.1002/cncr.24492

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4156–4166, 15 September 2009

Additional Information

How to Cite

Caglar, H. B., Baldini, E. H., Othus, M., Rabin, M. S., Bueno, R., Sugarbaker, D. J., Mentzer, S. J., Jänne, P. A., Johnson, B. E. and Allen, A. M. (2009), Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer, 115: 4156–4166. doi: 10.1002/cncr.24492

Author Information

  1. 1

    Department of Radiation Oncology Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts

  2. 2

    Department of Biostatistics Dana-Farber Cancer Institute, Boston, Massachusetts

  3. 3

    Department of Medical Oncology Dana-Farber Cancer Institute, Boston, Massachusetts

  4. 4

    Division of Thoracic Surgery Brigham and Women's Hospital, Boston, Massachusetts

  1. †

    Fax: (617) 632-4247

*Department of Radiation Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02215

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 23 JUN 2009
  3. Manuscript Accepted: 11 FEB 2009
  4. Manuscript Revised: 3 FEB 2009
  5. Manuscript Received: 5 JUN 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (177K)

References

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
    Direct Link:
  • 2
    Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol. 2007; 25: 4146-4152.
  • 3
    Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000; 18: 2981-2989.
  • 4
    Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol. 2005; 23: 5910-5917.
  • 5
    Rolland E, Le Pechoux C, Curran WK, et al. Concomitant radio-chemotherapy (CT-RT) versus sequential CT-RT in locally advanced non-small-cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs) [abstract]. Int J Radiat Oncol Biol Phys. 2007; 69: S5. Abstract 9.
  • 6
    Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13: 1880-1892.
  • 7
    Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2000; 70: 1826-1831.
  • 8
    Albain KS, Swain RS, Rusch VR, et al; North American Lung Cancer Intergroup. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) [abstract]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005; 23( 16S; pt I of II). Abstract 7014.
  • 9
    Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005; 23: 1530-1537.
  • 10
    Allen AM, Mentzer SJ, Yeap BY, et al. Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer. 2008; 112: 1106-1113.
    Direct Link:
  • 11
    DeVita VT Jr, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology: Lung Cancer. Philadelphia, Pa: Lippincott Williams & Wilkins, 2006.
  • 12
    Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001; 92: 1213-1223.
    Direct Link:
  • 13
    Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 1998; 16: 3316-3322.
  • 14
    Rusch VW, Albain KS, Crowley JJ, et al. Neoadjuvant therapy: a novel and effective treatment for stage IIIB non-small cell lung cancer. Southwest Oncology Group. Ann Thorac Surg. 1994; 58: 290-294; discussion 294-295.
  • 15
    Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003; 21: 2004-2010.
  • 16
    Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007; 25: 1698-1704.
  • 17
    Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005; 23: 5883-5891.
  • 18
    Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003; 57: 875-890.
  • 19
    Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC). Enough to convert no-elective into elective nodal irradiation (ENI)? Radiother Oncol. 2004; 71: 123-125.
  • 20
    Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997; 17: 147-161.
  • 21
    Teo P, Tai TH, Choy D, Tsui KH. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1988; 14: 867-871.
  • 22
    Pigott KH, Saunders MI. The long-term outcome after radical radiotherapy for advanced localized non-small cell carcinoma of the lung. Clin Oncol (R Coll Radiol). 1993; 5: 350-354.
  • 23
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; R Foundation for Statistical Computing; 2006. Available at: http://www.R-project.org. Accessed June 2009.
  • 24
    Langer CJ, Moughan J, Movsas B, et al. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer. 2005; 48: 93-102.
  • 25
    Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group study (S9504). Clin Lung Cancer. 2006; 8: 116-121.
  • 26
    Movsas B, Moughan J, Langer C, et al., Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801 [abstract]. 2007 ASCO Annual Meeting Proceedings, part 1. J Clin Oncol. 2007; 18S(June 20 suppl). Abstract 7529.
  • 27
    Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002; 20: 3454-3460.
  • 28
    Takeda S, Maeda H, Okada T, et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg. 2006; 30: 184-189.
  • 29
    Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007; 134: 188-193.
  • 30
    Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004; 78: 1200-1205; discussion 1206.
  • 31
    Daly BD, Fernando HC, Ketchedjian A, Dipetrillo TA, Kachnic LA, Morelli DM, et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg. 2006; 82: 227-231.
  • 32
    Curran W Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 94-10 [abstract]. Proc Am Soc Clin Oncol. 2000; 19. Abstract 1891.
  • 33
    Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in 5 Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998; 42: 469-478.
  • 34
    Huang EH, Liao Z, Cox JD, et al. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007; 68: 779-785.
  • 35
    Socinski MA, Zhang C, Herndon JE 2nd, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol. 2004; 15: 1033-1041.
  • 36
    Schild SE, McGinnis WL, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1106-1111.
  • 37
    Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002; 54: 348-356.
  • 38
    Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 741-747.
  • 39
    Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005; 63: 324-333.
View Full Article (HTML) Get PDF (177K)